Clinical Trial Diversity
Clinical trial diversity is the intentional inclusion of participants from varied racial, ethnic, socioeconomic, geographic, and health backgrounds to reflect populations affected by the condition being studied.
What is Clinical Trial Diversity?
Clinical trial diversity focuses on aligning study populations with real-world disease prevalence. Historically, many clinical trials have underrepresented communities of color, rural populations, older adults, and lower-income groups.
Regulatory expectations increasingly emphasize diversity planning. However, meaningful diversity entails more than enrollment targets. It requires trusted community partnerships, culturally aligned messaging, and sustained engagement as ongoing initiatives.
Acclinate supports clinical trial diversity by combining community insight with measurable engagement upstream from enrollment. This helps sponsors design outreach efforts that are credible, responsive, and informed by lived experience, while empowering underrepresented groups with education and shared space.
Clinical trial diversity strengthens scientific rigor, improves data relevance, and supports equitable access to research participation.
FAQ
Is clinical trial diversity required by regulators?
Sponsors are expected to submit diversity action plans outlining strategies for underrepresented groups.
Does diversity improve trial outcomes?
Yes. It strengthens generalizability and increases confidence in treatment safety and efficacy.
When should diversity planning begin?
From the beginning stages of clinical trials, well before recruitment starts.
%20(1).webp)
.webp)